1 ASX blue-chip share and one small-cap share to buy in 2026: experts

These businesses could be compelling opportunities.

Experts from the fund manager Wilson Asset Management (WAM) have outlined some stocks that could be opportunities. I'm going to highlight one ASX blue-chip share and one ASX small-cap share.

One business is from the WAM Leaders Ltd (ASX: WLE) portfolio, which is a listed investment company (LIC) that focuses on the larger companies on the ASX. The other company is from the WAM Microcap Ltd (ASX: WMI) portfolio.

Let's get into those ideas. While they may not be some of the most well-known businesses on the ASX, they may be just as capable of delivering good returns for investors, if not more because the market isn't paying them a lot of attention.  

A trendy woman wearing sunglasses splashes cash notes from her hands.

Image source: Getty Images

Whitehaven Coal Ltd (ASX: WHC)

WAM described Whitehaven Coal as a leading Australian coal producer with "high-quality assets and a robust balance sheet".

The investment team in charge of WAM Leaders revealed that the LIC recently increased its holding of Whitehaven Coal shares as coal prices began to "firm" after bottoming earlier in the year.

The ASX blue-chip share continues to deliver sound operational results despite a challenging backdrop and is executing cost-reducing initiatives with increased volumes at Blackwater and Daunia mines expected to "drive unit cost reductions from FY27".

The fund manager also noted that Whitehaven Coal maintains strong capital management flexibility, supporting shareholder returns through share buybacks and dividends.

Artrya Ltd (ASX: AYA)

WAM said that Artrya is a medical technology company focused on the detection and management of coronary artery disease and utilises artificial intelligence (A) to deliver accurate and non-invasive diagnoses in emergency and primary care settings.

The fund manager noted that the Artrya share price increased in December after Artrya announced it had secured its second US commercial customer, signing a three-year agreement with Northeast Georgia Health System (NGHS), one of its US foundation partners.

The agreement has a minimum value of US$0.3 million for the Salix Coronary Anatomy platform, with additional upside from per-scan fees for add-on modules.

It also supports Artrya's US growth strategy by moving a foundation partner into a paying customer and creating a reference site for further hospital contract wins.

Importantly, the Salix platform is expected to be rolled out across NGHS' five hospitals and broader network, signalling scope for wider adoption beyond an initial implementation.

WAM said Artrya also pointed to its Atlanta-based customer success team as a key enabler of smooth deployment and scalable customer onboarding as it grows in the US. The approval of Artrya's Heartflow Analysis module and additional customer contract wins are key near-term catalysts.

Both of these ASX shares could be pleasing opportunities at the current share prices.

Motley Fool contributor Tristan Harrison has positions in Wam Microcap. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

rubbish bins
Opinions

I've always loved Wesfarmers shares. But after a trip to Kmart, I'm not so sure

A weekend trip took some gloss off this stock.

Read more »

Piles of increasing coins alongside an hourglass.
Opinions

Why I'm planning to buy more Soul Patts shares in 2027

I think Soul Patts is a great long-term buy.

Read more »

a close up of a woman's face looks skywards as she is showered in a sea of graphic symbols of gold and silver coins bearing the bitcoin logo.
Cryptocurrencies

Are you a 'greater fool' for owning Bitcoin?

Is Bitcoin truly an investment?

Read more »

A woman in a red dress holding up a red graph.
Opinions

I went looking for shares which could double by 2030. These 3 made my shortlist

All of these shares are in recovery mode.

Read more »

A little girl is surprised at a science experiment.
Opinions

2 ASX shares with the potential to double in a year, and the risk that keeps me cautious

One of these ASX shares could climb up to 123% higher.

Read more »

A man in business attire plunges into water.
Opinions

My 2027 ASX shortlist started with 50 shares. It ended with these 3

There's no such thing as a perfect ASX share, but these three tick my boxes.

Read more »

A man in a business suit uses a rope to climb up the side of a huge pile of papers fashioned like a tall building against a blue sky backdrop with clouds representing an assessment of whether CBA shares stacked up well in March
Opinions

CBA shares: I investigated the bull and bear case. Here's my verdict

The market is split, so I did my own research.

Read more »

A couple hang off their car looking at the sun rising over the horizon.
Opinions

There's one ASX share I'd happily hold for 10 years. This is it

I think this ASX share can stand the test of time.

Read more »